comparemela.com

Latest Breaking News On - Stina singel - Page 1 : comparemela.com

Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024

-  40% of efficacy-evaluable patients (2 out of 5) in the initial cohort of patients with anti-PD-1 refractory melanoma treated with TransCon IL-2.

United-states
Copenhagen
Køavn
Denmark
American
Chicago-may
Stina-singel
Melinda-baker
Ascendis-pharma
Tim-lee
Head-of-clinical-development
Exchange-commission

Ascendis Pharma A/S (NASDAQ:ASND) Q1 2024 Earnings Call Transcript

Operator: Good day, and welcome to the Q1 2024 Ascendis Pharma Earnings Conference Call. At this time, all participants are in a listen-only mode.

United-kingdom
Germany
Austria
Austrian
German
Gavin-clark-gartner
Jessica-fye
Stina-singel
Tim-lee
Joseph-schwartz
David-lebowitz
Li-watsek

Ascendis Pharma A/S (NASDAQ:ASND) Q4 2023 Earnings Call Transcript

Operator: Good day, and thank you for standing by. Welcome to the Fourth Quarter 2023 Ascendis Pharma Earnings Conference Call. At this time, all participants are in a listen-only mode.

Germany
United-states
Austria
German
America
Jessica-fye
Joseph-schwartz
Tim-lee
David-lebowitz
Ascendis-pharma
Li-watsek
Stina-singel

Ascendis Pharma A/S (NASDAQ:ASND) Q3 2023 Earnings Call Transcript

Operator: Hello, and welcome to Ascendis Pharma Third Quarter 2023 Earnings Conference Call and Webcast.

Japan
Germany
Osaka
United-kingdom
German
Tim-lee
Jessica-fye
Scott-smith
Transcon-ptas
Jan-mikkelsen
Stina-singel
Ascendis-pharma

Ascendis Presents Updated and New TransCon IL-2 β⁄γ Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types at ESMO 2023

26.10.2023 -   Clinical responses with TransCon IL-2 β⁄γ demonstrated as monotherapy or in combination with checkpoint inhibitor, including in two of three small cell lung cancer patients treated with combination therapy  TransCon IL-2 β⁄γ administered every . Seite 1

Copenhagen
Køavn
Denmark
Spain
Madrid
Stina-singel
Ascendis-pharma
Head-of-clinical-development
European-society-of-medical-oncology
Believe-trial
European-society
Medical-oncology

vimarsana © 2020. All Rights Reserved.